# Xsensio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xsensio-s-a

- Industry: Healthcare IT
- Headquarters: Lausanne, Switzerland
- Website: www.xsensio.com/
- Total disclosed funding: $7M
- Latest round: Series A (Mar 2, 2026)
- Investors on record: 3

## About

Xsensio S.A. is a Switzerland-based company focusing on innovative healthcare technologies, providing advanced solutions for real-time monitoring of critical health biomarkers through its Lab-on-Skin™ sensing platform.Founded in 2014 in Lausanne, Switzerland, Xsensio S.A. specializes in healthcare technology, particularly in the realm of continuous health monitoring. In March 2026, Xsensio S.A. raised USD 7 million in Series A funding led by WI Harper Group, with participation from Privilege Ventures and European Innovation Council. Xsensio specializes in advanced healthcare technologies, primarily offering its flagship product, the Lab-on-Skin™ sensing platform. This innovative platform is designed for real-time, continuous monitoring of critical biomarkers, such as inflammation, enabling earlier detection of clinical deterioration across diverse settings, including ICUs, outpatient care, and home environments. The Lab-on-Skin™ sensing chip, developed at the Nanolab of the Swiss Federal Institute of Technology, utilizes semiconductor-based technology to provide unprecedented capabilities in health monitoring. The platform is particularly aimed at addressing high-impact challenges in critical care, oncology, and post-surgical recovery, serving a client base that includes healthcare providers and institutions seeking to enhance patient monitoring. Geographically, Xsensio’s products are marketed in Europe and North America, focusing on regions where there is a strong demand for innovative healthcare solutions.Xsensio’s revenue model is structured around B2B transactions, primarily targeting healthcare facilities and providers. The company generates income through the sales of its Lab-on-Skin™ sensing platform, which may involve direct sales agreements or partnerships with healthcare institutions. These transactions are designed to provide clients with actionable data that can facilitate timely clinical decisions. While specific pricing plans for individual products or services are not disclosed, the value proposition of the Lab-on-Skin™ technology is focused on improving patient outcomes and efficiency in monitoring, which is critical for healthcare providers. The revenue from these transactions is driven by the growing demand for continuous health monitoring solutions in healthcare systems across the regions served. The company is focused on introducing new products that enhance health monitoring capabilities, although specific details about upcoming product releases have not been disclosed. Moreover, Xsensio aims to expand its presence beyond current markets in Europe and North America, with specific geographic regions targeted for future growth expected to be identified based on demand. 

The company will use the March 2026 funding to accelerate the development and clinical validation of its Lab-on-Skin wearable biosensing platform to support clinical decision-making.

## Funding rounds

- Series A, Mar 2, 2026, $7M — WI Harper Group, Privilege Ventures, European Innovation Council

## Investors

- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series A
- Privilege Ventures (https://capitalatlas.ai/funds/privilege-ventures) — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A